Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month's 48% Selloff
11:19am, Monday, 16'th Feb 2026
Hims & Hers Health (NYSE:HIMS) has crashed 47.96% over the past month, falling from $31.32 on January 14 to $16.30 as of February 13.
Analysts Estimate Hims & Hers Health, Inc. (HIMS) to Report a Decline in Earnings: What to Look Out for
11:00am, Monday, 16'th Feb 2026
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Weekend Morning Brew: AI Jitters, Novo--Hims Clash, McDonald's Beat
07:37am, Saturday, 14'th Feb 2026
Weekly Market HighlightsWeekly breadth was slightly negative with 4,703 advancers versus 4,832 decliners, even as 963 stocks gained more than 10% and 1,151 fel
Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of “Hold” by Brokerages
01:28am, Saturday, 14'th Feb 2026
Shares of Hims and Hers Health, Inc. (NYSE: HIMS - Get Free Report) have been given a consensus recommendation of "Hold" by the seventeen analysts that are presently covering the company, Marketbeat R
Top 10 Most Shorted Stocks: CleanSpark, Hims & Hers And More
03:32pm, Friday, 13'th Feb 2026
Traders targeting heavily shorted stocks are looking to play one of two sides: betting on a company's downfall or hunting for a short squeeze.
Hims & Hers Falls Over 50% as Novo Files Obesity Lawsuit
02:08pm, Friday, 13'th Feb 2026
Short sellers are pressing their advantage in Hims and Hers Health (HIMS) as legal overhang reshapes the narrative around its weight-loss push. The shares have fa
Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows
08:22am, Friday, 13'th Feb 2026
Hedge fund bets against Hims & Hers Health hit their highest in at least a year in January, just before the online telehealth firm clashed with Novo Nordisk over its cut-price weight-loss pill, accord
A Historic Opportunity For Dividend Investors To Win Big
07:50am, Friday, 13'th Feb 2026
AI panic crushed SaaS and dragged down BDCs and asset managers. Trading at steep discounts and high dividend yields, we think that this is a historic opportunity. We explain why the market got it wron
US could take action including fines against Hims after brief Wegovy copy launch
06:05am, Friday, 13'th Feb 2026
The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill,
Hims & Hers Strengthens Integrated Personalized Digital Care Platform
11:01am, Thursday, 12'th Feb 2026
HIMS is scaling its personalized, at-home digital care model with new testosterone, menopause and Labs launches as subscribers near 2.5 million.
First Look: McDonald's beats, Hims sued, WBD deal battle
07:39am, Thursday, 12'th Feb 2026
Stock News Futures edge up as jobs data and earnings mix: U.S. stock futures inched higher after January payrolls rose 130,000 with unemployment at 4.3%, compli
Novo Nordisk CEO on Hims Suit, Wegovy Demand and Pricing
04:07pm, Wednesday, 11'th Feb 2026
Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg's Katie Greifeld to discuss GLP-1 supply, pricing and the company's lawsuit a
Novo says it's suing Hims to stop obesity drug copycats
04:02pm, Wednesday, 11'th Feb 2026
Novo Nordisk Chief Executive Officer Maziar Mike Doustdar says it's suing Hims & Hers for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegov
HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?
12:15pm, Wednesday, 11'th Feb 2026
Hims & Hers expands into new specialties and proactive testing while revenue and subscribers grow. However, regulatory, legal and margin pressures raise concerns.
HIMS Selloff Creates De-Risked Entry
10:24am, Wednesday, 11'th Feb 2026
HIMS Selloff Creates De-Risked Entry
